Columbia Financial (NASDAQ:CLBK – Get Free Report) is anticipated to announce its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect the company to announce earnings of $0.13 per share and revenue of $56.20 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.
Columbia Financial (NASDAQ:CLBK – Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. The firm had revenue of $63.88 million for the quarter, compared to analyst estimates of $53.20 million. Columbia Financial had a net margin of 1.24% and a return on equity of 3.58%. On average, analysts expect Columbia Financial to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Columbia Financial Price Performance
CLBK stock opened at $14.37 on Thursday. Columbia Financial has a 52-week low of $12.64 and a 52-week high of $19.28. The business has a fifty day moving average of $14.97 and a two-hundred day moving average of $14.56. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of 239.50 and a beta of 0.34. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.14.
Hedge Funds Weigh In On Columbia Financial
Institutional investors and hedge funds have recently modified their holdings of the company. Occudo Quantitative Strategies LP lifted its position in Columbia Financial by 27.7% in the second quarter. Occudo Quantitative Strategies LP now owns 15,093 shares of the company’s stock valued at $219,000 after acquiring an additional 3,274 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Columbia Financial by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,384 shares of the company’s stock worth $246,000 after acquiring an additional 702 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Columbia Financial by 8.1% during the second quarter. The Manufacturers Life Insurance Company now owns 17,949 shares of the company’s stock worth $260,000 after acquiring an additional 1,342 shares during the period. Rafferty Asset Management LLC increased its stake in shares of Columbia Financial by 60.8% during the second quarter. Rafferty Asset Management LLC now owns 22,330 shares of the company’s stock worth $324,000 after acquiring an additional 8,444 shares during the period. Finally, Quantinno Capital Management LP grew its position in Columbia Financial by 130.1% during the second quarter. Quantinno Capital Management LP now owns 23,297 shares of the company’s stock worth $338,000 after buying an additional 13,171 shares during the period. Institutional investors and hedge funds own 12.72% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (d)” rating on shares of Columbia Financial in a research report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $16.00.
Check Out Our Latest Stock Report on CLBK
About Columbia Financial
Columbia Financial, Inc, a bank holding company, provides various financial services to businesses and consumers in the United States. Its deposit products include checking, interest-earning checking products and municipal, savings and club deposits, and money market accounts, as well as certificates of deposit.
Further Reading
- Five stocks we like better than Columbia Financial
- Short Selling – The Pros and Cons
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Stock Market Upgrades: What Are They?
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Columbia Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Columbia Financial and related companies with MarketBeat.com's FREE daily email newsletter.